ClinicaliQ Trial Snapshot
- Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia — Recruiting • Phase III • Cardiology / Cardiovascular • NCT06597019.
- Sponsor: Novartis Pharmaceuticals.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to
Eligibility Snapshot
- : * Male or female participants, 6 to 130 mg/dL (3.4 mmol/L) at screening * For participants 8 to 2x ULN (except patients with Gilbert's syndrome) * Pregnant or nursing females * Recent and/or planned use of other investigational medicinal products or devices
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.